Tetramethylpyrazine
Names
[ CAS No. ]:
1124-11-4
[ Name ]:
Tetramethylpyrazine
[Synonym ]:
Pyrazine, 2,3,5,6-tetramethyl-
MFCD00006146
Chuanxingzine
Ligustrazine
2,3,5,6-Tetramethylpyrazine
EINECS 214-391-2
2,3,5,6,-Tetramethyl-1,4-pyrazine
PPyrazine, tetramethyl-
Tetramethyl-1,4-diazine
Tetramethylpyrazine
2,3,5,6-TETRA METHYL PYRAZINE
Biological Activity
[Description]:
[Related Catalog]:
[In Vitro]
[References]
Chemical & Physical Properties
[ Density]:
1.0±0.1 g/cm3
[ Boiling Point ]:
192.7±35.0 °C at 760 mmHg
[ Melting Point ]:
77-80 °C(lit.)
[ Molecular Formula ]:
C8H12N2
[ Molecular Weight ]:
136.19
[ Flash Point ]:
71.6±17.6 °C
[ Exact Mass ]:
136.100052
[ PSA ]:
25.78000
[ LogP ]:
1.56
[ Vapour Pressure ]:
0.7±0.4 mmHg at 25°C
[ Index of Refraction ]:
1.504
[ Stability ]:
Stable. Incompatible with strong acids, strong oxidizing agents.
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- UQ3905000
- CHEMICAL NAME :
- Pyrazine, tetramethyl-
- CAS REGISTRY NUMBER :
- 1124-11-4
- LAST UPDATED :
- 199701
- DATA ITEMS CITED :
- 4
- MOLECULAR FORMULA :
- C8-H12-N2
- MOLECULAR WEIGHT :
- 136.22
- WISWESSER LINE NOTATION :
- T6N DNJ B1 C1 E1 F1
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 1910 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- DCTODJ Drug and Chemical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.1- 1977/78- Volume(issue)/page/year: 3,249,1980
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 800 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- IJCREE International Journal of Crude Drug Research. (Swets & Zeitlinger B.V., POB 825, 2160 SZ Lisse, Netherlands) V.20- 1982- Volume(issue)/page/year: 23,119,1985
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 239 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- CMJODS Chinese Medical Journal (Beijing, English Edition). (China International Book Trading Corp., POB 2820, Beijing, Peop. Rep. China) V.1- 1975- Adopted vol. no. 92 in 1979. Volume(issue)/page/year: 4,319,1978
Safety Information
[ Symbol ]:
GHS05, GHS07
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H302-H315-H318-H335
[ Precautionary Statements ]:
P261-P280-P305 + P351 + P338
[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves
[ Hazard Codes ]:
Xn:Harmful
[ Risk Phrases ]:
R22
[ Safety Phrases ]:
S26-S39-S24/25
[ RIDADR ]:
NONH for all modes of transport
[ WGK Germany ]:
3
[ RTECS ]:
UQ3905000
[ HS Code ]:
29339990
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2933990090
[ Summary ]:
2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Articles
J. Food Sci. 80 , C1476-89, (2015)
Enzymatic extrusion, instead of traditional steam cooking, to treat rice is an efficient and alternative pretreatment for Chinese rice wine fermentation. In order to determine the formation of volatil...
Induction of human CYP3A4 by huperzine A, ligustrazine and oridonin through pregnane X receptor-mediated pathways.Pharmazie 69(7) , 532-6, (2014)
The pregnane X receptor (PXR) is a key regulator of CYP3A4, which is involved in catalyzing the metabolic conversion of a number of endogenous substrates. In this study, we screened 22 compounds isola...
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.Bioorg. Med. Chem. 16 , 8868-74, (2008)
Ischemic stroke results from brain blood vessel blockage by thrombus, and produces neuronal cell damage and death. While thrombolytic therapy with tPA has achieved some success in clinic, the strategy...